Travere Therapeutics shares are trading higher after Wedbush maintained an Outperform rating on the stock and raised its price target from $17 to $25.
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics shares rose after Wedbush maintained an Outperform rating and increased its price target from $17 to $25.
October 09, 2024 | 4:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Travere Therapeutics shares increased following Wedbush's decision to maintain an Outperform rating and raise the price target from $17 to $25.
The increase in price target and maintained Outperform rating by Wedbush is a positive signal to investors, likely boosting short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100